Single administration of vildagliptin attenuates postprandial hypertriglyceridemia and endothelial dysfunction in normoglycemic individuals

Noguchi,Kaoru; Hirota,Minoru; Miyoshi,Toru; Tani,Yoshinori; Noda,Yoko; Ito,Hiroshi; Nanba,Seiji

doi:10.3892/etm.2014.2051

Single administration of vildagliptin attenuates postprandial hypertriglyceridemia and endothelial dysfunction in normoglycemic individuals

Authors:
- Kaoru Noguchi
- Minoru Hirota
- Toru Miyoshi
- Yoshinori Tani
- Yoko Noda
- Hiroshi Ito
- Seiji Nanba
View Affiliations

Affiliations: Department of Cardiology, Okayama Rosai Hospital, Okayama 702-8055, Japan, Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700‑8558, Japan
Published online on: November 5, 2014 https://doi.org/10.3892/etm.2014.2051
Pages: 84-88

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Postprandial hypertriglyceridemia impairs endothelial function and plays an important role in the development of atherosclerosis. The aim of the present study was to examine the postprandial effects of the dipeptidyl peptidase‑4 inhibitor vildagliptin and the α‑glucosidase inhibitor voglibose on endothelial dysfunction and lipid profiles following a single administration. A randomized cross‑over trial using 11 normoglycemic individuals was performed. The postprandial effects of a single administration of vildagliptin (50 mg) or voglibose (0.3 mg) on endothelial function were analyzed using brachial artery flow‑mediated dilation (FMD) and lipid profiles during fasting and 1.5 and 3 h after an oral cookie‑loading test. Compared with voglibose, vildagliptin significantly suppressed postprandial endothelial dysfunction, (%FMD, ‑1.6±0.9 vildagliptin vs. ‑4.0±0.7 voglibose; P=0.01) and the postprandial incremental increase in the triglyceride level (28±18 vildagliptin vs. 51±26 mg/dl voglibose; P=0.01) 3 h after a cookie‑loading test. In addition, vildagliptin significantly increased the levels of glucagon‑like peptide‑1 compared with voglibose 3 h after a loading cookie test (4.4±0.6 vs. 2.9±0.7 pmol/l, respectively; P=0.04). No significant differences in the levels of glucose, apolipoprotein B‑48, glucagon or insulin were observed between vildagliptin and voglibose treatments. In conclusion, a single administration of vildagliptin attenuated postprandial endothelial dysfunction and postprandial hypertriglyceridemia, suggesting that vildagliptin may be a promising antiatherogenic agent.

View Figures

View References

1	Bansal S, Buring JE, Rifai N, et al: Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 298:309–316. 2007. View Article : Google Scholar : PubMed/NCBI
2	Nordestgaard BG, Benn M, Schnohr P and Tybjaerg-Hansen A: Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 298:299–308. 2007. View Article : Google Scholar : PubMed/NCBI
3	Véniant MM, Pierotti V, Newland D, et al: Susceptibility to atherosclerosis in mice expressing exclusively apolipoprotein B48 or apolipoprotein B100. J Clin Invest. 100:180–188. 1997. View Article : Google Scholar : PubMed/NCBI
4	Bae JH, Bassenge E, Kim KB, et al: Postprandial hypertriglyceridemia impairs endothelial function by enhanced oxidant stress. Atherosclerosis. 155:517–523. 2001. View Article : Google Scholar : PubMed/NCBI
5	van Oostrom AJ, Sijmonsma TP, Verseyden C, et al: Postprandial recruitment of neutrophils may contribute to endothelial dysfunction. J Lipid Res. 44:576–583. 2003. View Article : Google Scholar : PubMed/NCBI
6	DeFronzo RA, Fleck PR, Wilson CA and Mekki Q: Alogliptin Study 010 Group: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care. 31:2315–2317. 2008. View Article : Google Scholar : PubMed/NCBI
7	Feng J, Zhang Z, Wallace MB, et al: Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem. 50:2297–2300. 2007. View Article : Google Scholar : PubMed/NCBI
8	Moritoh Y, Takeuchi K, Asakawa T, Kataoka O and Odaka H: Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice. Eur J Pharmacol. 588:325–332. 2008. View Article : Google Scholar : PubMed/NCBI
9	Matikainen N, Mänttäri S, Schweizer A, et al: Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia. 49:2049–2057. 2006. View Article : Google Scholar : PubMed/NCBI
10	Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ and Couture P: Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes Metab. 13:366–373. 2011. View Article : Google Scholar : PubMed/NCBI
11	Noda Y, Miyoshi T, Oe H, et al: Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: a preliminary report. Cardiovasc Diabetol. 12:82013. View Article : Google Scholar : PubMed/NCBI
12	Ayaori M, Iwakami N, Uto-Kondo H, et al: Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients. J Am Heart Assoc. 2:e0032772013. View Article : Google Scholar : PubMed/NCBI
13	Nakamura K, Oe H, Kihara H, et al: DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study. Cardiovasc Diabetol. 13:1102014. View Article : Google Scholar : PubMed/NCBI
14	Hiki M, Shimada K, Kiyanagi T, et al: Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease - Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic patients with coronary heart disease (J-MACH). Circ J. 74:1471–1478. 2010. View Article : Google Scholar : PubMed/NCBI
15	Basu A, Charkoudian N, Schrage W, et al: Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab. 293:E1289–E1295. 2007. View Article : Google Scholar : PubMed/NCBI
16	Ceriello A, Esposito K, Testa R, et al: The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an ‘endothelial resistance’ to glucagon-like peptide 1 in diabetes. Diabetes Care. 34:697–702. 2011. View Article : Google Scholar : PubMed/NCBI
17	Nyström T, Gutniak MK, Zhang Q, et al: Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 287:E1209–E1215. 2004. View Article : Google Scholar : PubMed/NCBI
18	Hattori Y, Jojima T, Tomizawa A, et al: A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Diabetologia. 53:2256–2263. 2010. View Article : Google Scholar : PubMed/NCBI
19	Qin X, Shen H, Liu M, et al: GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats. Am J Physiol Gastrointest Liver Physiol. 288:G943–G949. 2005. View Article : Google Scholar : PubMed/NCBI
20	Wøjdemann M, Wettergren A, Sternby B, et al: Inhibition of human gastric lipase secretion by glucagon-like peptide-1. Dig Dis Sci. 43:799–805. 1998. View Article : Google Scholar : PubMed/NCBI
21	Hsieh J, Longuet C, Baker CL, et al: The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia. 53:552–561. 2010. View Article : Google Scholar
22	Kato T, Inoue T and Node K: Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study. Cardiovasc Diabetol. 9:122010. View Article : Google Scholar : PubMed/NCBI
23	Kitano D, Chiku M, Li Y, et al: Miglitol improves postprandial endothelial dysfunction in patients with acute coronary syndrome and new-onset postprandial hyperglycemia. Cardiovasc Diabetol. 12:922013. View Article : Google Scholar : PubMed/NCBI
24	Masuda D, Nakagawa-Toyama Y, Nakatani K, et al: Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia. Eur J Clin Invest. 39:689–698. 2009. View Article : Google Scholar : PubMed/NCBI